Pancreatic Cancer Research

ResearcherNational Institutes of HealthNo recent work listed

Jian Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5335-8845; OpenAlex author ID A5100370460. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
114
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers

Papers 20

  1. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  2. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  3. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  4. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Co-author DOI 10.1097/mpa.0000000000002175↗
  5. MicroRNA-216a targets WT1 expression and regulates KRT7 transcription to mediate the progression of pancreatic cancer-A transcriptome analysis. Last author DOI 10.1002/iub.2468↗
  6. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.1002/ijc.32733↗
  7. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2020.11866↗
  8. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  9. Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. Last author DOI 10.1080/15384101.2018.1520558↗
  10. miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Last author DOI 10.1038/cddis.2017.530↗
  11. NO• and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. Co-author DOI 10.1089/ars.2016.6809↗
  12. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Last author DOI 10.1186/s12943-017-0723-7↗
  13. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  14. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0511↗
  15. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.18632/oncotarget.10323↗
  16. Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. Co-author DOI 10.2147/ott.s95744↗
  17. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  18. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  19. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Co-author DOI 10.1016/j.canlet.2013.03.001↗
  20. Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Co-author DOI 10.1007/s10552-011-9856-y↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoxiao Zhang · 3 shared papers, 2022–2023 · strength 0.45
  2. Shiwei Guo · 3 shared papers, 2022–2023 · strength 0.45
  3. Xiaoyi Yin · 3 shared papers, 2022–2023 · strength 0.45
  4. S. Perwez Hussain · 5 shared papers, 2016–2020 · strength 0.39
  5. Ming Zhan · 4 shared papers, 2016–2018 · strength 0.30
  6. Suizhi Gao · 2 shared papers, 2023 · strength 0.29
  7. Lingyu Zhu · 2 shared papers, 2023 · strength 0.29
  8. Shuo Shen · 2 shared papers, 2023 · strength 0.29
  9. Xiaohan Shi · 2 shared papers, 2023 · strength 0.29
  10. Bo Li · 2 shared papers, 2022–2023 · strength 0.29
  11. Gang Jin · 2 shared papers, 2022–2023 · strength 0.29
  12. Yongwei Sun · 4 shared papers, 2015–2022 · strength 0.28
  13. Shouhui Yang · 4 shared papers, 2016–2020 · strength 0.24
  14. Nader N Hanna · 4 shared papers, 2016–2020 · strength 0.24
  15. Β. Michael Ghadimi · 4 shared papers, 2016–2020 · strength 0.24
  16. Jochen Gaedcke · 4 shared papers, 2016–2020 · strength 0.24
  17. H. Richard Alexander · 4 shared papers, 2016–2020 · strength 0.24
  18. Matthias M. Gaida · 4 shared papers, 2016–2020 · strength 0.24
  19. Ruimeng Yang · 3 shared papers, 2017–2018 · strength 0.23
  20. Wei Wang · 1 shared paper, 2021 · strength 0.19
  21. Jihui Hao · 3 shared papers, 2015–2022 · strength 0.17
  22. Deliang Fu · 3 shared papers, 2015–2022 · strength 0.17
  23. Gang Y Jin · 1 shared paper, 2023 · strength 0.16
  24. Hui Jiang · 1 shared paper, 2023 · strength 0.16
  25. Yang Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.